Bharat Immunological Biological Corporation Ltd vs Gujarat Terce Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.47 as of 18 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 12.42 crore as compare to the Sep '25 revenue of ₹ 12.98 crore. This represent the decline of -4.31% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 1.26 crore as compare to the Sep '25 ebitda of ₹ 1.94 crore. This represent the decline of -35.05% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0.76 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man.
Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs. Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands. By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.
As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Gujarat Terce Laboratories Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Gujarat Terce Laboratories Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr while Market cap of Gujarat Terce Laboratories Ltd is 28 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Gujarat Terce Laboratories Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Gujarat Terce Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Gujarat Terce Laboratories Ltd?

As of May 18, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.47. On the other hand, Gujarat Terce Laboratories Ltd stock price is INR ₹36.04.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Gujarat Terce Laboratories Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Gujarat Terce Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.